$PSTI Pluristem Expands its Compassionate Use Prog

$PSTI Pluristem Expands its Compassionate Use Program:
Treated First COVID-19 Patient in U.S. Under FDA Single
Patient Expanded Access Program

• Cleared by FDA to proceed with the treatment in U.S. under Coronavirus Treatment
Acceleration Program (CTAP)
• Pluristem’s main focus: multinational clinical trial of PLX cells for treatment of
complications associated with COVID-19
HAIFA, Israel, April 13, 2020 - Pluristem Therapeutics Inc. (Nasdaq STI) (TASE STI), a leading
regenerative medicine company developing a platform of novel biological therapeutic products,
announced today that it has treated its first patient suffering from COVID-19 complications in the
United States under the U.S. Food and Drug Administration’s (FDA) Single Patient Expanded
Access Program, also called a compassionate use program, which is part of the U.S. Coronavirus
Treatment Acceleration Program (CTAP), an emergency program for possible therapies that uses
every available method to move new treatments to patients as quickly as possible.

https://www.pluristem.com/wp-content/uploads/...ELEASE.pdf